Skip to content

Released May 13, 2026, before the open

10-Q filed May 13, 2026, 43 days after period end · 0001104659-26-059756

Q1 2026 · 10-Q
Revenue$33.75M+233.7% vs Q1 2025+270.0% vs Q4 2025
Net Income$18.32MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted$0.22N/M vs Q1 2025no prior Q4 2025 on file
Operating Income$21,146,000N/M
Operating Cash Flow$22,025,000N/M
Free Cash Flowderived$21,264,000N/M
Margins · derived
Operating margin62.7%+103.6 pt vs Q1 2025
Net margin54.3%+90.1 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$33.75M$10.11M$3.75M$9.59M
Net Income$18.32M-$3.62M-$4.60M-$3.13M
EPS Diluted$0.22-$0.05-$0.06-$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR